Maravai LifeSciences To Host Earnings Conference Call on Monday, May 8, 2023
Rhea-AI Summary
Maravai LifeSciences, Inc. (NASDAQ: MRVI) is set to release its first quarter 2023 financial and operating results on May 8, 2023, after market close. A conference call is scheduled for the same day at 2:00 p.m. PT / 5:00 p.m. ET. Investors can participate by calling (800) 715-9871 or (646) 307-1963 and referring to Conference ID 9951216. The call will also be available via live or archived webcast on the Investors section of Maravai's website.
Maravai is a prominent life sciences company that provides essential products facilitating the development of drug therapies, diagnostics, and vaccines. The company supports leading biopharmaceutical, vaccine, diagnostics, and gene therapy organizations.
Positive
- None.
Negative
- None.
News Market Reaction – MRVI
In the trading session that priced this news, MRVI gained 0.35%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2023 financial and operating results after the market closes on Monday, May 8, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
To participate in the conference call by telephone, dial (800) 715-9871 or (646) 307-1963 and reference Maravai LifeSciences, Conference ID 9951216. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
